Hepatitis C
📧 Sign up to get email alerts when something new happens for Hepatitis C.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-02-12Clinical Trial Update: Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2 [Phase 3]
Phase 3 study of BI 207127 in combination with faldaprevir and ribavirin for hepatitis C, including peginterferon-ineligible patients; resul…
-
CLINICAL_TRIALS trial_result · 2016-02-11Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults [Phase 3]
Phase 3 trial evaluating three experimental hepatitis C drugs against Telaprevir in treatment-experienced adults has completed with results …
-
CLINICAL_TRIALS trial_result · 2016-02-10Clinical Trial Update: An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria
An observational study evaluating peginterferon alfa-2a plus ribavirin for hepatitis C in Austria has completed, with results posted in 2016…
-
CLINICAL_TRIALS trial_result · 2016-02-10Clinical Trial Update: An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C
An observational study evaluating the effects of cumulative ribavirin dose in participants with chronic hepatitis C; the trial has completed…
-
CLINICAL_TRIALS trial_result · 2016-02-09Clinical Trial Update: A Study of Administration of Peginterferon Alfa-2a [Pegasys] by Autoinjector Versus Pre-filled Syringe in Patients With Chronic Hepatitis C [Phase 1]
A Phase 1 study evaluating autoinjector versus pre-filled syringe administration of Peginterferon alfa-2a (Pegasys) for chronic hepatitis C;…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-02-05Clinical Trial Update: SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection [Phase 3]
Phase 3 trial evaluating sofosbuvir-based regimens with ribavirin for 16 or 24 weeks and with pegylated interferon for 12 weeks in adults wi…
-
CLINICAL_TRIALS trial_result · 2016-02-04Clinical Trial Update: Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003) [Phase 1]
Phase 1 trial update evaluating safety, pharmacokinetics, and pharmacodynamics of MK-8876 in participants with hepatitis C infection has com…
-
CLINICAL_TRIALS trial_result · 2016-02-02Clinical Trial Update: A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C. [Phase 4]
Phase 4 trial update evaluating NeoRecormon (epoetin beta) for anemia in patients with hepatitis C; the study has completed.
-
CLINICAL_TRIALS trial_result · 2016-02-01Clinical Trial Update: Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection [Phase 2]
Phase 2 trial assessing safety, antiviral activity, and pharmacokinetics of BI 207127 plus BI 201335 with or without ribavirin over 4 to 40 …
-
CLINICAL_TRIALS trial_result · 2016-01-29Clinical Trial Update: Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects [Phase 1]
Phase 1 proof-of-concept study evaluating the safety and preliminary efficacy of EDP239 in adults with hepatitis C; the trial has completed.
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) [Phase 1]
Phase 1 study evaluating the drug-drug interaction between IDX719 and simeprevir in healthy participants; related to Chronic Hepatitis C Inf…
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) [Phase 1]
Phase 1 pharmacokinetic study evaluating IDX719 in participants with normal and impaired hepatic function to support dosing considerations i…
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006) [Phase 1]
This clinical trial update reports the completion of a Phase 1 open-label study to compare the relative bioavailability of Samatasvir (IDX18…
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) [Phase 1]
Phase 1 study evaluating potential drug-drug interactions among IDX719, simeprevir, TMC647055, and ritonavir in healthy participants.
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease [Phase 1, Phase 2]
The document reports completion of a Phase 1/2 safety study evaluating a pegylated interferon variant (PEG-IFN-SA) for hepatitis C infection…
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects [Phase 1]
Phase 1 clinical trial update for IDX21459 assessing single and multiple doses in healthy and Hepatitis C-infected subjects; the study statu…
-
CLINICAL_TRIALS trial_result · 2016-01-22Clinical Trial Update: To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006) [Phase 1]
Phase 1 pharmacokinetic study evaluating whether ritonavir or omeprazole affects exposure to samatasvir (IDX719) in healthy participants; th…
-
CLINICAL_TRIALS trial_result · 2016-01-22Clinical Trial Update: A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002) [Phase 1]
A Phase 1 study evaluated the potential drug-drug interaction between IDX320 and IDX184 in healthy participants, related to chronic hepatiti…
-
CLINICAL_TRIALS trial_result · 2016-01-21Clinical Trial Update: ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection. [Phase 4]
Phase 4 study evaluating Pegasys (peginterferon alfa-2a) in combination with COPEGUS (ribavirin) in interferon-naive patients with chronic h…
-
CLINICAL_TRIALS trial_result · 2016-01-20Clinical Trial Update: A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C [Phase 4]
A Phase 4 clinical trial update reports results for ribavirin in combination with Pegasys (pegylated interferon alfa-2a) in patients with ch…
-
CLINICAL_TRIALS trial_result · 2016-01-18Clinical Trial Update: Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection
A completed clinical trial comparing two triple regimens for treatment and retreatment of chronic Hepatitis C infection.
-
CLINICAL_TRIALS trial_result · 2016-01-15Clinical Trial Update: SHO-SAIKO-TO for Patients With Chronic Hepatitis C: A Phase II Study [Phase 2]
Phase II clinical trial update showing results for SHO-SAIKO-TO in chronic hepatitis C; the study has completed and results were posted in 2…
-
CLINICAL_TRIALS trial_result · 2016-01-14Clinical Trial Update: REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination Therapy [Phase 4]
Phase 4 study evaluating peginterferon alfa-2a (40 kDa) plus ribavirin in chronic hepatitis C patients who did not respond to prior peginter…
-
CLINICAL_TRIALS trial_result · 2016-01-11Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus [Phase 2]
Phase 2 study evaluating a 12-week combination therapy of TMC647055 and TMC435 with and without GSK23336805, plus a pharmacokinetic enhancer…
-
CLINICAL_TRIALS trial_result · 2016-01-05Clinical Trial Update: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures [Phase 3]
A Phase 3 trial evaluating a four-drug regimen (ombitasvir/paritaprevir/ritonavir + dasabuvir) with or without ribavirin for Hepatitis C in …